These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

89 related items for PubMed ID: 8176202

  • 1. Donor T cells can be induced to grow and survive long term in vivo without previous host immunosuppression.
    Chen W, Cheever MA.
    J Immunol; 1994 May 15; 152(10):4767-74. PubMed ID: 8176202
    [Abstract] [Full Text] [Related]

  • 2. Adoptively transferred antigen-specific T cells can be grown and maintained in large numbers in vivo for extended periods of time by intermittent restimulation with specific antigen plus IL-2.
    Chen W, Reese VA, Cheever MA.
    J Immunol; 1990 May 15; 144(10):3659-66. PubMed ID: 2332628
    [Abstract] [Full Text] [Related]

  • 3. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
    Naito K, Pellis NR, Kahan BD.
    Cancer Res; 1988 Jan 01; 48(1):101-8. PubMed ID: 3257158
    [Abstract] [Full Text] [Related]

  • 4. Treatment of disseminated leukemia with cyclophosphamide and immune cells: tumor immunity reflects long-term persistence of tumor-specific donor T cells.
    Greenberg PD, Cheever MA.
    J Immunol; 1984 Dec 01; 133(6):3401-7. PubMed ID: 6149246
    [Abstract] [Full Text] [Related]

  • 5. Antigen-driven T cell clones can proliferate in vivo, eradicate disseminated leukemia, and provide specific immunologic memory.
    Klarnet JP, Matis LA, Kern DE, Mizuno MT, Peace DJ, Thompson JA, Greenberg PD, Cheever MA.
    J Immunol; 1987 Jun 01; 138(11):4012-7. PubMed ID: 3108381
    [Abstract] [Full Text] [Related]

  • 6. Retroviral transduction of protein kinase C-gamma into tumor-specific T cells allows antigen-independent long-term growth in IL-2 with retention of functional specificity in vitro and ability to mediate tumor therapy in vivo.
    Chen W, Schweins E, Chen X, Finn OJ, Cheever MA.
    J Immunol; 1994 Oct 15; 153(8):3630-8. PubMed ID: 7930583
    [Abstract] [Full Text] [Related]

  • 7. Interleukin-2 administered in vivo induces the growth and augments the function of cultured T cells in vivo.
    Cheever MA, Thompson JA, Kern DE, Greenberg PD.
    J Biol Response Mod; 1984 Oct 15; 3(5):462-7. PubMed ID: 6334133
    [Abstract] [Full Text] [Related]

  • 8. Interleukin 2 administered in vivo induces the growth of cultured T cells in vivo.
    Cheever MA, Greenberg PD, Irle C, Thompson JA, Urdal DL, Mochizuki DY, Henney CS, Gillis S.
    J Immunol; 1984 May 15; 132(5):2259-65. PubMed ID: 6609193
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
    Chin CS, Miller CH, Graham L, Parviz M, Zacur S, Patel B, Duong A, Bear HD.
    Int Immunol; 2004 Sep 15; 16(9):1283-94. PubMed ID: 15262898
    [Abstract] [Full Text] [Related]

  • 11. Long-term survival of adoptively transferred tumor-infiltrating lymphocytes in mice.
    Alexander RB, Rosenberg SA.
    J Immunol; 1990 Sep 01; 145(5):1615-20. PubMed ID: 1974569
    [Abstract] [Full Text] [Related]

  • 12. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M, Kjaergaard J, Kuppen PJ, Nannmark U, Agger R, Hokland P, Basse P.
    In Vivo; 1999 Sep 01; 13(3):199-204. PubMed ID: 10459491
    [Abstract] [Full Text] [Related]

  • 13. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer.
    Bristol JA, Schlom J, Abrams SI.
    Cell Immunol; 1999 May 25; 194(1):78-89. PubMed ID: 10357883
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. T-cells for tumor therapy can be obtained from antigen-loaded sponge implants.
    Chen W, Reese VA, Cheever MA.
    Cancer Res; 1994 Feb 15; 54(4):1065-70. PubMed ID: 8313363
    [Abstract] [Full Text] [Related]

  • 16. Depletion of donor-reactive cells as a new concept for improvement of mismatched bone marrow engraftment using reduced-intensity conditioning.
    Prigozhina TB, Elkin G, Khitrin S, Slavin S.
    Exp Hematol; 2004 Nov 15; 32(11):1110-7. PubMed ID: 15539090
    [Abstract] [Full Text] [Related]

  • 17. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
    Chapoval AI, Fuller JA, Kremlev SG, Kamdar SJ, Evans R.
    J Immunol; 1998 Dec 15; 161(12):6977-84. PubMed ID: 9862733
    [Abstract] [Full Text] [Related]

  • 18. Potential for specific cancer therapy with immune T lymphocytes.
    Cheever MA, Greenberg PD, Fefer A.
    J Biol Response Mod; 1984 Dec 15; 3(2):113-27. PubMed ID: 6233396
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2.
    Roychowdhury S, May KF, Tzou KS, Lin T, Bhatt D, Freud AG, Guimond M, Ferketich AK, Liu Y, Caligiuri MA.
    Cancer Res; 2004 Nov 01; 64(21):8062-7. PubMed ID: 15520217
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.